# Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

> **NCT00083213** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 25 (actual)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** ziv-aflibercept

## Key facts

- **NCT ID:** NCT00083213
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2008-05
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083213, "Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00083213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*